文献速递乳腺癌支持与姑息治疗

SOX5驱动软骨内骨化维持乳腺癌残留细胞休眠

Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy.
PubMed 文献 · Cancer Discov · 2026-01-01

该研究通过CRISPR-Cas9筛选发现转录因子SOX5和SOX6是肿瘤复发的功能调控因子。SOX5缺失加速局部和转移部位复发,并促进治疗相关及微环境诱导的休眠逃逸。SOX5驱动休眠残留肿瘤细胞采用软骨内骨化程序,该程序经[18F]NaF-PET成像确认,并在逃逸休眠的复发肿瘤中逆转。患者新辅助治疗后残留病灶富集骨软骨生成表达特征,原发乳腺癌中该特征富集预测无复发生存改善。

要点

  • SOX5缺失加速乳腺癌局部和转移复发并促进休眠逃逸
  • SOX5驱动残留肿瘤细胞软骨内骨化程序维持休眠
  • [18F]NaF-PET可读出该程序并可能指导分层治疗

核心结论

  • SOX5依赖的中胚层转分化是强化肿瘤细胞休眠、防止复发的适应性机制。

研究设计与样本

  • 研究采用CRISPR-Cas9筛选鉴定肿瘤复发的功能调控因子,并在小鼠模型及患者样本中验证。

主要发现

  • SOX5缺失在局部和转移部位均加速复发,并在治疗相关和微环境诱导情境中促进休眠逃逸。
  • SOX5驱动休眠残留肿瘤细胞采用软骨内骨化程序,经[18F]NaF-PET成像确认,并在逃逸休眠的复发肿瘤中逆转。
  • 患者新辅助治疗后残留病灶富集骨软骨生成表达特征,原发乳腺癌中该特征富集预测无复发生存改善。

临床怎么用

  • 可将[18F]NaF-PET作为该过程的影像学读出,用于分层患者接受微小残留病灶靶向或休眠强化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Recurrent breast cancer accounts for most disease-associated mortality and can develop decades after primary tumor therapy. Recurrences arise from residual tumor cells (RTC) that can evade therapy in a dormant state; however, the mechanisms enforcing dormancy in RTCs are poorly understood. CRISPR-Cas9 screening identified the transcription factors SOX5 and SOX6 as functional regulators of tumor recurrence. Loss of SOX5 accelerated recurrence at both local and metastatic sites and promoted dormancy escape in both therapy-associated and microenvironment-induced contexts. Remarkably, SOX5 drove dormant RTCs to adopt a cartilage-dependent bone development program, termed endochondral ossification, which was confirmed by [18F]NaF-positron emission tomography (PET) imaging and reversed in recurrent tumors escaping dormancy. Consistent with findings in mice, osteochondrogenic expression signatures in patients were enriched in residual disease following neoadjuvant therapy, and their enrichment in primary breast cancers predicted improved recurrence-free survival. These findings identify SOX5-dependent mesodermal transdifferentiation as an adaptive mechanism that prevents recurrence by reinforcing tumor cell dormancy. SIGNIFICANCE: Our study reveals a SOX5-mediated endochondral ossification program that maintains transdifferentiated breast cancer RTCs in a dormant state and predicts recurrence risk. Incorporating [18F]NaF-PET as an imaging-based readout of this process could stratify patients for minimal residual disease-targeting or dormancy-enforcing treatments, offering a transformative approach to personalize care for breast cancer survivors. See related commentary by Gonçalves and Correia, p. 626.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Sreekumar A, Blankemeyer E, Sterner CJ, et al. Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy. Cancer Discov. 2026. PMID: 41370830. doi:10.1158/2159-8290.CD-25-0919

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。